A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Trial Profile

A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs AMG 176 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 11 Apr 2018 Planned End Date changed from 30 Oct 2018 to 30 Apr 2019.
    • 16 Jan 2018 Planned End Date changed from 30 Apr 2019 to 30 Oct 2018.
    • 16 Jan 2018 Planned primary completion date changed from 30 Apr 2019 to 30 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top